04:15 , Mar 23, 2019 |  BioCentury  |  Product Development

Baby steps beyond beta amyloid

Companies are taking steps -- baby steps -- to test new targets in pathways such as neuroinflammation and neuroprotection as a means to treat Alzheimer’s disease. The failure of aducanumab won’t be the final nail...
15:56 , Apr 25, 2017 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Prostate cancer In vitro , cell culture and mouse studies suggest a guanidine-based inhibitor of the σ-1 receptor could help treat prostate cancer. Chemical synthesis and in vitro testing yielded a guanidine analog compound...
07:00 , Oct 10, 2016 |  BC Week In Review  |  Company News

Anavex, Biogen deal

Biogen will test Anavex’s ANAVEX 2-73 in an oligodendrocyte precursor cell differentiation assay. The assay may lead to an in vivo remyelination trial using a chemical demyelination model. ANAVEX 2-73, an aminotetrahydrofuran derivative agonist of...
07:00 , Aug 1, 2016 |  BC Week In Review  |  Clinical News

IV ANAVEX 2-73: Additional Phase IIa data

Anavex reported additional data from 32 patients with mild to moderate AD in an open-label, crossover, Australian Phase IIa trial of ANAVEX 2-73 showing that mean MMSE scores and ADCS-ADL scores were “maintained” through 31...
07:00 , Aug 1, 2016 |  BC Week In Review  |  Clinical News

Oral ANAVEX 2-73: Additional Phase IIa data

Anavex reported additional data from 32 patients with mild to moderate AD in an open-label, crossover, Australian Phase IIa trial of ANAVEX 2-73 showing that mean MMSE scores and ADCS-ADL scores were “maintained” through 31...
08:00 , Dec 7, 2015 |  BC Week In Review  |  Clinical News

Oral ANAVEX 2-73: Additional Phase IIa data

Data from 32 patients with mild to moderate AD in Part A of an open-label, crossover, Australian Phase IIa trial showed that ANAVEX 2-73 was well tolerated. Additionally, ANAVEX-273 improved MMSE score by 1.5 points...
08:00 , Dec 7, 2015 |  BC Week In Review  |  Clinical News

IV ANAVEX 2-73: Additional Phase IIa data

Data from 32 patients with mild to moderate AD in Part A of an open-label, crossover, Australian Phase IIa trial showed that ANAVEX 2-73 was well tolerated. Additionally, ANAVEX-273 improved MMSE score by 1.5 points...
08:00 , Nov 23, 2015 |  BC Week In Review  |  Clinical News

Oral ANAVEX 2-73 regulatory update

Anavex said it is planning a double-blind, placebo-controlled Phase II/III trial of ANAVEX 2-73 to treat Alzheimer’s disease after receiving guidance from FDA. The aminotetrahydrofuran derivative agonist of sigma-1 receptor and muscarinic receptor is in...
08:00 , Nov 2, 2015 |  BC Week In Review  |  Clinical News

IV ANAVEX 2-73: Completed Phase IIa enrollment

Anavex completed enrollment of 32 patients with mild to moderate AD in an open-label, crossover, Australian Phase IIa trial to evaluate ANAVEX 2-73. In part A of the trial, patients are receiving a 30 mg...
08:00 , Nov 2, 2015 |  BC Week In Review  |  Clinical News

Oral ANAVEX 2-73: Completed Phase IIa enrollment

Anavex completed enrollment of 32 patients with mild to moderate AD in an open-label, crossover, Australian Phase IIa trial to evaluate ANAVEX 2-73. In part A of the trial, patients are receiving a 30 mg...